Q1 Earnings Estimate for NKTR Issued By Zacks Research

Nektar Therapeutics (NASDAQ:NKTR) – Zacks Research issued their Q1 2028 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a report issued on Wednesday, April 1st. Zacks Research analyst Team expects that the biopharmaceutical company will post earnings per share of ($3.45) for the quarter. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics’ FY2028 earnings at ($13.82) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping the consensus estimate of ($2.69) by $0.91. The firm had revenue of $21.81 million during the quarter, compared to analysts’ expectations of $10.44 million. Nektar Therapeutics had a negative return on equity of 386.16% and a negative net margin of 297.07%.

NKTR has been the subject of a number of other research reports. William Blair raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. BTIG Research boosted their price objective on shares of Nektar Therapeutics from $118.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. TD Cowen started coverage on shares of Nektar Therapeutics in a report on Tuesday, March 17th. They issued a “buy” rating on the stock. Wedbush initiated coverage on shares of Nektar Therapeutics in a research note on Tuesday, March 24th. They set a “neutral” rating and a $70.00 target price for the company. Finally, Wall Street Zen cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $128.13.

Nektar Therapeutics Price Performance

Nektar Therapeutics stock opened at $75.71 on Thursday. Nektar Therapeutics has a one year low of $6.45 and a one year high of $78.81. The business’s fifty day moving average is $62.14 and its 200 day moving average is $56.38. The stock has a market capitalization of $2.17 billion, a PE ratio of -7.42 and a beta of 1.16.

Institutional Trading of Nektar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NKTR. AQR Capital Management LLC boosted its stake in shares of Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after acquiring an additional 2,807,595 shares during the period. Integrated Wealth Concepts LLC bought a new stake in Nektar Therapeutics during the 1st quarter valued at approximately $68,000. Rhumbline Advisers lifted its holdings in Nektar Therapeutics by 23.3% in the 1st quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 41,948 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in Nektar Therapeutics in the 2nd quarter worth approximately $1,297,000. Finally, Marshall Wace LLP bought a new position in Nektar Therapeutics in the 2nd quarter worth approximately $367,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Nektar Therapeutics

In related news, insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the transaction, the insider directly owned 21,354 shares in the company, valued at approximately $761,697.18. The trade was a 15.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Howard W. Robin sold 423 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the sale, the chief executive officer directly owned 75,489 shares of the company’s stock, valued at $5,510,697. This represents a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 4,470 shares of company stock worth $181,955. Insiders own 5.25% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.